Emily Willingham is a journalist whose work has appeared at The Washington Post, San Francisco Chronicle, NPR, and others.
Maker iBeat said that it has 11,000 preorders for its Heart Watch device, which registers changes in heart rate and blood flow that might signal cardiac arrest and sends for help from a network of Good Samaritans trained on CPR.
The San Francisco startup has a cloud-based platform to prevent supply chain mistakes in personalized cell and gene therapy where patients' re-engineered cells need to be delivered back to the correct individual.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Adcetris made by Seattle Genetics for classical stage III or stage IV Hodgkin lymphoma has received FDA approval for use in combination with chemotherapy for previously untreated disease.
The company, which is using an AI-based platform to comb through drug candidates in a much shorter time than traditional approaches require, just raised $10 million.
Judge Kiyo Matsumoto has sentenced the poster child for pharmaceutical company greed to seven years after a jury found him guilty on one count of conspiracy to commit securities fraud and two counts of securities fraud.
The Food and Drug Administration has granted 23andMe the first-ever authorization for direct-to-consumer genetic testing for cancer risk without a prescription.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
A new report from the Alliance of Regenerative Medicine shows what a record year the sector had in 2017 with a 78.5 percent year-over-year funding increase to more than $7.5 billion.
Bad news has piled up at Axovant, including the poor showing of its Parkinsons/Lewy body drug, and now the CEO David Hung is out after a mere 10 months on the job.
Whether it's attempting to cure cancer or buying a troubled newspaper like the LA Times, Dr. Patrick Soon-Shiong has a penchant for the spotlight.